Vanrafia is an oral treatment for adults with primary IgA nephropathy at risk of rapid disease progression. It reduces proteinuria and helps protect kidney function by blocking endothelin A receptors.
To Get Full Access :
To Get Full Access :
Vanrafia is an oral treatment for adults with primary IgA nephropathy at risk of rapid disease progression. It reduces proteinuria and helps protect kidney function by blocking endothelin A receptors.
The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
